Oral Mucositis is a frequent complication of cancer chemotherapy or of radiation therapy to the head & neck region. Treatments include frequent mouth cleansing and rinsing with buffered saline and fluoride solutions and administration of topical and systemic antimicrobial agents. Mucositis has remained to be a major complication for cancer patients, despite the usual oral care treatments.
MuGard is a new treatment of Oral Mucositis, which is a viscous, mucoadhesive rinse which provides a protective coating to the oral mucosa. In comparison of patients undergoing standard care with patients using MuGard, the instance and severity of mucositis with the MuGard group was significantly lower.
Clinical trials of of MuGard have shown, when compared to historical data from two different sources for patients at risk of developing mucositis and patients who have received prior standard of treatment, that mucositis sores as measured by the oral mucositis assessment scale (OMAS) were lower for patients using MuGard than in patients receiving standard care.